VolitionRx Limited (VNRX)

Market Cap	23.58M -54.3%
Revenue (ttm)	1.73M +40.0%
Net Income	-23.36M
EPS	-0.22
Shares Out	137.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,937,687
Open	0.1928
Previous Close	0.2000
Day's Range	0.1700 - 0.1928
52-Week Range	0.1700 - 0.9400
Beta	1.33
Analysts	Strong Buy
Price Target	2.00 (+1,066.18%)
Earnings Date	May 14, 2026

About VNRX

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment r...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cameron Reynolds
• Employees: 75
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: VNRX
• Website: https://volition.com

Financial Performance

In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price target is $2.0, which is an increase of 1,066.18% from the latest price.

Price Target

$2.0

(1,066.18% upside)

Analyst Consensus: Strong Buy